The healthcare firm focuses on innovative interventional therapy for major diseases in the cardiovascular and respiratory fields.
The Series E Round investment was jointly undertaken by VMS Investment Group and Primavera Capital Group with the same funds and the additional investment was completed by existing investors Simiao Capital and Sequoia China.
As the largest single financing in the global RDN field so far, this round of financing will be mainly used to accelerate the global clinical registration test of multiple innovative medical device products of SyMap, develop a new generation of RDN and respiratory intervention disruptive innovative products and acquire overseas innovative technologies and product lines. The company will build a unique and innovative active technology platform in the fields of chronic diseases such as hypertension, heart failure, arrhythmia, asthma and early lung cancer and will aim to become a global leader in the intermediary treatment of cardiovascular and respiratory fields.
The healthcare firm was jointly founded by Wang Jie, a global top expert in the cardiovascular field, former president of Medical School of Nanjing University, former executive vice president of Jiangsu Institute of clinical medicine, Jiangsu Provincial People's Hospital, Professor of Cardiology of Medical School of Columbia University and Jin Kewen, a senior medical industry person. Previously, it has obtained investment from well-known investment institutions including Softbank China Capital, Sequoia China, Yipu Capital and Simiao Capital.
At present, giants such as Medtronic, Philips and Otsuka continue to deploy in the RDN field and large-scale clinical trials home and abroad have accumulated rich data. In April of this year, in Hainan, Medtronic's Symplicity Spyral catheter system was applied clinically for the first time in China and the first renal artery sympathetic radiofrequency ablation was completed. Domestic firms Kangfeng Biology and Meiliweiye are also in the field of renal artery ablation and are entering the clinical trial stage. For hypertensive patients trapped in drug therapy, minimally invasive interventional RDN technology provides a new possibility for lowering blood pressure.